Perspective Therapeutics (CATX) said Tuesday it has treated the first patient in a phase 1/2a dose-finding trial to evaluate the safety and initial anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha.
Patient selection is based on single-photon emission computed tomography, or SPECT imaging using [203Pb]PSV359, the company said.
Fibroblast activation protein alpha is a protein commonly found on the surface of cancer-associated fibroblasts in the stroma, a component of the tumor microenvironment in most epithelial cancers, the company said.
Shares of Perspective Therapeutics were down more than 2% in recent Tuesday trading.
Price: 2.40, Change: -0.06, Percent Change: -2.24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.